title: [Tumor necrosis factor receptors sTNF-RI and sTNF-RII in advanced chronic heart failure].
abstract: The inflammatory process in chronic heart failure (CHF) is the result of dysbalance between the function of inflammatory and natural antiinflammatory mediators. Tumor necrosis factor alpha (TNF-alpha) is increased in patients with severe CHF. Two soluble proteins, the extracellular domains of the TNF receptors (sTNF-RI and sTNF-RII) inhibit the TNF-alpha biological effect. The aim of the study was to examine the plasma levels of sTNF-RI and sTNF-RII in patients with CHF and its relation to clinical, biochemical parameters of CHF severity. 41 patients with CHF (NYHA III and NYHA IV) and 18 control subjects were enrolled in this study. Plasma levels of sTNF-RI and sTNF-RII were analyzed by immunosorbent assay (ELISA) kits R&D (Research and Diagnostics Systems) (pg/ml).
  
  
  RESULTS
  CHF patients had significantly increased receptor plasma levels compared to controls (p < 0.001). Soluble sTNF-RI and sTNF-RII receptors levels were similar in class NYHA III and NYHA IV. Receptor sTNF-RII correlated negatively with sodium plasma levels (p < 0.001), and sTNF-RI positively correlated with urice acid plasma level (p < 0.05). No statistically significant correlations were found between those receptors and age and gender etiology and severity of CHF, body weight (BMI) or other examined parameters (clinical, hemodynamic, echocardiographic, holter).
  
  
  CONCLUSIONS
  Plasma level of sTNF-RI and sTNF-RII are increased in patients with CHF.
authors.affiliation: III Katedra i Oddział Kliniczny Kardiologii Sl. AM, Slaskie Centrum Chorób Serca w Zabrzu.
authors.forename: Jolanta
authors.initials: J
authors.lastname: Nowak
authors.forename: Piotr
authors.initials: P
authors.lastname: Rozentryt
authors.forename: Marta
authors.initials: M
authors.lastname: Szewczyk
authors.forename: Marek
authors.initials: M
authors.lastname: Gierlotka
authors.forename: Agata
authors.initials: A
authors.lastname: Duszańska
authors.forename: Bozena
authors.initials: B
authors.lastname: Szyguła
authors.forename: Romuald
authors.initials: R
authors.lastname: Wojnicz
authors.forename: Michał
authors.initials: M
authors.lastname: Hawranek
authors.forename: Lech
authors.initials: L
authors.lastname: Poloński
authors.forename: Marian
authors.initials: M
authors.lastname: Zembala
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000097:blood*; D015992:Body Mass Index; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood*; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D012720:Severity of Illness Index; D012737:Sex Factors; D018709:Statistics, Nonparametric
chemical_list: D015703:Antigens, CD; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II